Author: admin

AutoScaled Roofers Launches AI-Powered Lead Generation System, Transforming Roofing Businesses

The AI-powered lead generation and appointment solution delivers hands-free, exclusive, high-quality leads for unmatched efficiency and growth.

AutoScaled Roofers, a premier marketing partner for roofing contractors in the USA, is excited to announce the launch of its AI-powered lead generation and appointment system. Designed to deliver exclusive, high-quality roofing leads on autopilot, this cutting-edge solution enables roofing companies to consistently book 15-20 qualified appointments per month—without the hassle of manual follow-up.

As a leader in the roofing marketing industry, AutoScaled Roofers has perfected lead generation for contractors, allowing them to focus on closing deals while the company handles the hard work of securing booked in-home estimates. This AI-driven system marks a major milestone in the company’s ongoing mission to help roofing businesses maximize revenue and growth.

“Our automated lead nurturing approach takes the stress, guesswork, and wasted time out of lead generation,” said Anthony Apostolidis, founder of AutoScaled Roofers.

Anthony emphasized how AI is reshaping lead generation, making it easier than ever for roofers to scale their businesses. He explained that the system uses advanced AI technology to generate leads through Facebook and Instagram advertising, then nurtures those leads to ensure contractors connect only with fully qualified homeowners. “Our goal with AutoScaled Roofers is simple: provide roofers with hands-free, high-converting leads that guarantee measurable business growth.”

Game-Changing AI Lead Generation for Roofers

AutoScaled Roofers is redefining how roofers grow their businesses. Unlike conventional marketing strategies, the company’s fully automated system identifies and engages homeowners in specific service areas, qualifies their interest in roofing services, and schedules appointments automatically.

The system also guarantees 100% exclusive leads through a one-roofer-per-market partnership model, ensuring that clients receive high-intent leads without competition. Plus, AutoScaled Roofers operates on a pay-on-results basis—contractors only pay after securing successful client engagements. “We’re not just generating leads; we’re delivering an all-in-one system that helps roofers close deals on autopilot,” added Anthony.

Proven Results & Free Consultation Offer

AutoScaled Roofers has already generated thousands of booked inspections for roofing contractors across the U.S. By combining battle-tested marketing strategies with its AI-powered system, the company ensures that clients never have to chase leads again.

To help roofing contractors experience the potential of this groundbreaking system, AutoScaled Roofers is offering a $1,500 value in free resources to those who book a consultation. The introductory call includes a no-commitment demo of how the system delivers 15-20 qualified leads per month, helping roofing businesses scale predictably and profitably.

For more information or to schedule a consultation, visit https://autoscaledroofers.com/info.

About AutoScaled Roofers:

AutoScaled Roofers is a leading marketing agency specializing in helping roofing contractors generate a consistent flow of qualified roof inspections every month. The company leverages AI technology and digital marketing expertise to provide automated lead generation and appointment scheduling, empowering roofers to close more deals effortlessly.

Media Contact
Company Name: AutoScaled Roofers
Contact Person: Anthony Apostolidis
Email: Send Email
Phone: +1 855-596-6443
Country: United States
Website: autoscaledroofers.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AutoScaled Roofers Launches AI-Powered Lead Generation System, Transforming Roofing Businesses

FIC Live | Discover Nutrition and Health Firsthand… Don’t Miss Out

As spring bursts forth with fresh energy, the much-awaited Food Ingredients China (FIC 2025) commenced on March 17 at the National Exhibition and Convention Center in Shanghai. Hailed as Asia’s largest, most international, and most authoritative event within the food industry, FIC 2025 has lured more than a thousand of the world’s leading companies. The event spotlights innovations in food additives, ingredients, condiments, and raw materials for functional foods, presenting the latest products, technologies, and solutions.

Innovation for a Healthier Future – NHU Showcased Its Comprehensive Nutrition and Health Solutions

As an innovator within the food additives and ingredients industry, NHU made a remarkable impression at FIC 2025 with a diverse array of advanced products and solutions in the nutrition and health sector. Highlighting its expertise, NHU put on display more than 10 core products, including the COVITAS vitamin series (VA, VB6, VB12, VC, VD3, VE, and biotin), the COAMINOS amino acid series (serine, the L – cysteine series, and taurine), along with pigments and coenzyme Q10 – all shining like pearls at the exhibition.

01 Exploring a Healthy Future with an Innovative Product Matrix

Solutions presented at the exhibition:

Nutritional Ingredients for Health: Tailored for Every Age Group

In children’s schoolbags, fruity vitamin gummies supply the essential vitamins picky eaters need; in the desks of the white-collars, coenzyme Q10 capsules help support heart endurance during late nights; and for the elderly, microencapsulated vitamin D3 powder, which dissolves in water, protects bone health.

NHU’s COVITAS vitamin series is designed to meet the unique nutritional needs of each age group.

Romance on the Tongue: Enjoy Unique Flavors and Colors of Food and Beverage

As dawn breaks, the convenience store fridge cradles bottles of orange juice, its beta-carotene transforming it into a shimmering amber, as if each drop holds the morning glow of citrus groves. By afternoon, the bakery window reveals a colorful surprise, where mango mousse and blueberry cake come alive with rich, vibrant shades. Even the jelly shake in a child’s hand mirrors the playful orange hues, casting joyful ripples and drawing out pure, carefree smiles.

NHU leverages technology to bring colors to the palate, offering a lively and pleasurable encounter.

Invisible Guardian of Food: Nutrition Boost in Every Bite

In the school cafeteria, steamed buns made with vitamin A-fortified flour help preserve children’s eyesight. On supermarket shelves, vitamin E-enriched rapeseed oil offers additional antioxidant protection during cooking. Student milk, fortified with vitamins A and D, aids in bone growth like an invisible support system. The humble ingredients on the dining table quietly serve as the hidden protectors of every meal.

Glow from Within: The Intriguing Tie between Nutrition and Beauty

In the morning, L-cysteine essence acts like an invisible cloak, smoothing away the oxidative damage from late nights. As you groom in front of the mirror, L-serine scalp essence strengthens hair and eases worries about hair loss. In the shower, vitamin microbeads burst into a thousand flower-like buds upon contact with water, quietly renewing the skin barrier in the mist. These innovations, tucked away in life’s small moments, are redefining the essence of beauty.

02：Industry Synergy: Technological Innovation for Shared Success

Global Spotlight: Shaping the Future of Nutrition and Health

The space was buzzing with activity, as representatives from leading global food companies and experts from research institutions gathered around the NHU booth for in-depth discussions with the company’s sales team. There was a dynamic exchange of cutting-edge technologies, insightful industry perspectives, and collaborative negotiations, all of which fostered a strong foundation for future partnerships.

So far, the NHU booth has welcomed hundreds of visitors from Asia, Europe, the Americas, and beyond, resulting in numerous in-depth negotiations and setting the stage for future collaborations. With a focus on professional excellence and exceptional service, our NHU team has effectively reached new customer segments.

Taking advantage of FIC 2025, a crucial platform, NHU is poised to deepen its global customer relationships. By aligning closely with market needs, addressing key industry challenges, and exploring innovative solutions, we aim to create an open, mutually beneficial industrial ecosystem—driving sustainable industry growth with great products and cutting-edge technologies.

From March 17th to 19th, visit the NHU booth (3B20-3C21). Together, we’ll dive into the latest products and technologies, explore the future of nutrition and health, share valuable industry insights, and work together to build a brighter tomorrow.

Media Contact
Company Name: Lingrong Culture
Contact Person: Wang Yurong
Email: Send Email
Phone: 2134007851
Address:3185 Wilshire blvd
City: Los Angeles
State: CA
Country: United States
Website: www.lingrongculture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FIC Live | Discover Nutrition and Health Firsthand… Don’t Miss Out

Dream Cinema Productions “Night Mistress” Now Available on Amazon Prime Via Adler Entertainment

“Night Mistress”, the latest motion picture by Ray Michaels Quiroga’s Dream Cinema Productions in now available for purchase and streaming via Adler Entertainment on Amazon Prime.

“Night Mistress” is written and directed by Philip Cable with Co-Director Ray Michaels Quiroga, and is based on the best-selling novel of the same name. Get your copy on Amazon today:

https://www.amazon.com/PHILIP-CABLES-NIGHT-MISTRESS-Philip/dp/B095556G9Q/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=1695406660&sr=8-1

Dream Cinema Productions’ “Night Mistress” – They Killed Her Man And She Took Monstrous Revenge….She Wasn’t A Monster…She Was Six Monsters In One!!!!

“Night Mistress” stars Hollywood Icons Brinke Stevens, Tracee Lee Cocco, Sharyn Wynters, Deborah Dutch, Rene Arranda, Ana Paula Lopes, and Ray Michaels Quiroga with guest appearances by Nick Palma and Danielle Kennedy. “Night Mistress” was co-produced by Francisco Roman, Judy Karman and Jimmy Star.

Ray Michaels Quiroga has an impeccable reputation in the world of Hollywood for working with Hollywood legends in his films, and along with the amazing cast of this film he has worked with Academy Award Winner Terry Moore, Calista Carradine, Pamela Hasselhoff, Sissy Wellman, John Saxon and Carla Laemmle.

Purchase/stream Dream Cinema Productions “Night Mistress” on Amazon Prime here:

https://www.primevideo.com/detail/0Q0DNSD9Z9MNMUZ1Q6YHUISCIO/ref=atv_dp_share_cu_r

Media Contact
Company Name: World Star PR
Contact Person: Jimmy Star
Email: Send Email
Phone: 631-506-6600
Country: United States
Website: https://www.facebook.com/WorldStarPR/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dream Cinema Productions “Night Mistress” Now Available on Amazon Prime Via Adler Entertainment

A Soul-Stirring Memoir of Redemption, Spiritual Awakening, and the Courage to Rise

“by Thomas Campbell”

In a time when the world is desperate for hope, healing, and honest voices, Thomas Campbell’s extraordinary memoir, From the Ashes Into the Light, arrives as a luminous beacon. Published by Book Writing Pioneer, this heartfelt and raw narrative traces the remarkable life of a man born into abandonment and adversity—who chose, instead of bitterness, to become a builder of light.

From the painful rejection of his own mother to surviving alone on the streets before the age of fifteen, Thomas Campbell’s life began in the shadows. But what makes his story truly extraordinary is not just the darkness he endured—but the light he uncovered within himself, a divine spark that refused to be extinguished by hardship, hatred, or hopelessness.

This is not a story of survival alone—it is a triumphant testimony of spiritual rebirth, divine purpose, and the power of self-realization.

An Unflinching Portrait of Pain—and a Map Toward Purpose

From the Ashes Into the Light is filled with the authenticity of a man who has walked through fire. Whether recounting nights spent sleeping in a car while his mother visited men, or the haunting silence of being called a “liability” by the very person who gave him life, Campbell never asks for pity—only reflection.

Every chapter is a vivid snapshot of a world many never see—where love is conditional, survival is a strategy, and hope is often hidden under layers of trauma. But within these pages, readers will also find extraordinary acts of grace: a grandmother’s warm embrace, the quiet dignity of a father suffering in silence, and the healing touch of strangers who became angels.

The L.I.G.H.T. Movement: Awakening the Divine Within

At the heart of Campbell’s journey is the revelation of The L.I.G.H.T.—a personal and spiritual philosophy born not in comfort, but in chaos. It stands for:

  • Living Intentionally with God’s Highest Truth
  • Integrity as the foundation of character
  • Giving of oneself with purpose and grace
  • Harmony with all humanity
  • Truth rooted in respect and devotion

Through The L.I.G.H.T., Campbell offers not just a message—but a movement. One that reclaims the idea that greatness is not reserved for the privileged, but born from within those who choose to rise despite the odds.

A Story That Speaks to the Forgotten, the Misunderstood, and the Brave

Whether you are a young person facing impossible odds, a parent seeking understanding, or a leader looking to reconnect with your purpose, From the Ashes Into the Light is a revelation. Campbell writes with the wisdom of a spiritual sage, the vulnerability of a wounded child, and the passion of a man on a mission to ignite transformation in others.

He reminds us that trauma is not the end—it’s the soil in which greatness can grow, if only we have the courage to dig deep.

“You were born with light inside you,” Campbell says. “You were not made to live in someone else’s darkness. Your life is not a mistake—it’s a masterpiece in progress.”

About the Author

Thomas Campbell is a visionary leader, entrepreneur, and advocate for spiritual empowerment and youth transformation. His experiences have shaped a philosophy that bridges faith, resilience, and leadership into one universal truth: that light lives in all of us—and it is our sacred duty to awaken it.

He is the founder of The L.I.G.H.T. initiative, dedicated to helping underserved communities and individuals discover their value, rebuild their lives, and lead with purpose.

https://www.the-light-project.net/

https://www.the-light-project.net/

Amazon https://a.co/d/iu5pUdg

Media Contact
Company Name: Book Writing Pioneer
Contact Person: Thomas Campbell
Country: United States
Website: https://bookwritingpioneer.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: A Soul-Stirring Memoir of Redemption, Spiritual Awakening, and the Courage to Rise

New Developments in Opioid Use Disorder Research Highlighting the Need for Integrated Care Approaches

Chicago, IL – A new study titled “Predictors of Mortality Among Patients With Opioid Use Disorder: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database” has uncovered critical factors influencing mortality among patients with Opioid Use Disorder. The research, led by Naga Venkata Satish Babu Bodapati, Sandipkumar Patel, Rana Veer Samara Sihman Bharattej Rupavath, Omkar Reddy Polu, Balaiah Chamarthi, and Chrishanti Anna Joseph, provides valuable insights that could improve survival outcomes for this vulnerable population.

The study found that mortality among patients with Opioid Use Disorder is significantly influenced by factors such as age, comorbidities, hospital characteristics, and healthcare disparities. These findings emphasize the urgent need for integrated care approaches that address both the medical and psychiatric conditions associated with Opioid Use Disorder. The research highlights the importance of providing holistic treatment strategies to improve patient outcomes and reduce mortality rates.

Ms. Emily Clark, Senior Journalist at Alpine Vision Media, stated, “This study offers vital insights into the complex factors that contribute to mortality among patients with Opioid Use Disorder. By recognizing the role of comorbidities and healthcare disparities, we can develop more targeted interventions that address the multifaceted needs of this population. In the United States, the opioid crisis continues to claim thousands of lives each year, with opioid-related deaths exceeding 100,000 annually. The findings from this research suggest that a more integrated care model, which includes coordinated medical and psychiatric treatment, could lead to improved survival rates”. These strategies, combined with harm reduction approaches, could significantly reduce the mortality rate among individuals struggling with Opioid Use Disorder.

Leading experts from around the world are already recognizing the importance of these findings. Dr. Eduardo J. Gómez, a prominent addiction specialist from Colombia, and Dr. Nasser Al-Ghanim, a leader in public health from Kuwait, both of whom have dedicated their careers to improving healthcare outcomes in underserved regions, acknowledge the value of integrated care in improving survival outcomes for patients with Opioid Use Disorder. Their work, alongside the insights from this study, could influence the global approach to addressing opioid addiction and its associated risks.

The study’s implications are far-reaching. “With over 16 million people suffering from opioid use disorder worldwide, these findings highlight the need for more comprehensive, patient-centered care strategies that focus on both physical and mental health. In addition to the health benefits, this research is poised to result in significant financial savings. The cost of opioid-related healthcare in the U.S. is astronomical, with opioid overdoses and related conditions contributing to over $78 billion annually in medical, lost productivity, and criminal justice costs. By reducing mortality rates and improving patient care through more targeted and integrated interventions, this research could save billions in healthcare expenditures. Optimizing the treatment approach for those with Opioid Use Disorder not only improves lives but also holds the potential to significantly alleviate the financial burden on healthcare systems worldwide,” stated Ms. Clark. Targeted interventions to mitigate high-risk factors and enhance harm reduction strategies will be essential for improving survival rates and reducing the burden of opioid-related mortality globally.

Citation: Bodapati N, Patel S, Sihman Bharattej Rupavath R, et al. (March 29, 2025) Predictors of Mortality Among Patients With Opioid Use Disorder: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database. Cureus 17(3): e81405. DOI 10.7759/cureus.81405

Media Contact
Company Name: Alpine Vision Media
Contact Person: Emily Clark
Email: Send Email
Country: Switzerland
Website: https://alpinevisionmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Developments in Opioid Use Disorder Research Highlighting the Need for Integrated Care Approaches

It’s All About Journey Through Faiths Crossroads

“Ronald D. Ackerson II”

Ronald D. Ackerson II’s Caught Between Two Covenants: The Church Mixture of Law & Grace takes a deep look at the tension between law and grace. In this book, he explores how many people in today’s faith community often feel caught between these two concepts. It’s interesting how he addresses this internal struggle and the way it shapes how we approach our faith. The book really invites readers to think about how we balance living according to law while also understanding and accepting grace. It’s a complex issue that’s both challenging and thought-provoking for anyone wrestling with these themes.

A Fresh Perspective on a Timeless Struggle

Through a meticulous exploration of scripture and history, Ackerson presents an accessible narrative that addresses the ongoing struggle to reconcile Old Testament law with the liberating grace introduced through Christ. The book unveils the spiritual and practical challenges of mixing law’s demands with grace’s freedom, offering insights that transcend denominational boundaries.

Key Themes:

  • The Crossing of Covenants: The journey from Sinaoi to Calvary and the profound transformation it signifies.
  • Freedom from Performance Mentality: Breaking the cycle of works-based faith to vale the gift of grace.
  • Building on a Foundation of Freedom: Practical guidance for cultivating a faith rooted in grace.
  • Living in Grace-Filled Maturity: How believers can grow spiritually while fully embracing their identity under the new convenant.


Transformation is a reflection

Ackerson really digs into the Bible’s take on law and grace, starting with their original purpose and showing how they’re ultimately fulfilled in Christ. He takes a closer look at how these two ideas shape not just our personal faith but also church culture and how we think about salvation as a whole. It’s one of those books that makes you think about how deeply these concepts influence everything from the way we practice our faith to the bigger picture of what salvation really means.

What Makes This Book A Perfect Guidance?

In a world grappling with issues of morality, justice, and faith, Caught Between Two Convenants offers clarity and hope. It provides readers with the tools to understand the complexities of their faith and to navigate their spiritual journey with confidence and assurance.

Meet Ronald Ackerson

Ronald D. Ackerson II is really passionate about helping believers gain a deeper understanding of God’s Word. You can tell through his teaching, ministry, and writing that he’s all about making these ideas clear and meaningful.

In Caught Between Two Covenants: The Church Mixture of Law & Grace, he offers a fresh take on the Christian faith, focusing on how grace transforms our lives. It’s definitely a thought-provoking read for anyone looking to explore these themes more deeply.

Amazon https://a.co/d/1IjrDGD

Media Contact
Company Name: Book Writing Pioneer
Contact Person: Ronald D. Ackerson II
Email: Send Email
Country: United States
Website: https://bookwritingpioneer.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: It’s All About Journey Through Faiths Crossroads

Short Bowel Syndrome Market Growth Projections 2024-2034: DelveInsight Analysis | Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma

The Key Short Bowel Syndrome Companies in the market include – Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others.

 

DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Short Bowel Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Short Bowel Syndrome Market Forecast

 

Some of the key facts of the Short Bowel Syndrome Market Report:

  • The Short Bowel Syndrome market size was valued approximately USD 2.3 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In March 2025, Ironwood Pharmaceuticals (Nasdaq: IRWD) was a biotechnology company dedicated to developing and commercializing transformative therapies for individuals with gastrointestinal (GI) and rare diseases. The company is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog designed for short bowel syndrome patients reliant on parenteral support. Additionally, Ironwood has been instrumental in developing LINZESS® (linaclotide), the leading U.S. prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

  • In December 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for glepaglutide. The long-acting GLP-2 analog is being developed to treat adult patients with short bowel syndrome (SBS) and intestinal failure (IF) who rely on parenteral support.

  • In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.

  • In 2023, the total market size for Short Bowel Syndrome in the US was estimated to be approximately USD 2,000 million, with Japan following closely behind.

  • In 2022, the United States reported the highest number of cases among the seven major markets, with a prevalence of 20,800 cases.

  • In 2022, Germany had the highest prevalence of Short Bowel Syndrome cases among the European Union Four (EU4) and the United Kingdom, with approximately 2,700 reported cases.

  • According to information released by the Crohn’s & Colitis Foundation of America, an estimated 10,000 to 20,000 individuals in the United States are affected by Short Bowel Syndrome.

  • According to information provided by PINNT, approximately 1,000 individuals in England are believed to have Short Bowel Syndrome, necessitating ongoing treatment with parenteral nutrition support.

  • Emerging therapies for Short Bowel Syndrome (SBS) comprise Glepaglutide, Apraglutide, HM15912, and various others. Ongoing research suggests the potential development of enhanced pharmacologic treatments targeting improved intestinal adaptation, regulation of gut motility, management of small bowel bacterial overgrowth, and addressing rejection issues following small intestinal transplantation.

  • Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others

  • Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others

  • The Short Bowel Syndrome epidemiology based on gender analyzed that Short Bowel Syndrome affects females more than males

  • The Short Bowel Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Short Bowel Syndrome pipeline products will significantly revolutionize the Short Bowel Syndrome market dynamics.

 

Short Bowel Syndrome Overview

Short Bowel Syndrome (SBS), also known as short gut syndrome, is a complex disorder that occurs when a significant portion of the small intestine is missing or nonfunctional. The small intestine is responsible for absorbing nutrients from the food we eat into the bloodstream. When a substantial portion of it is surgically removed due to conditions like Crohn’s disease, ischemic bowel disease, or traumatic injury, it can result in SBS.

 

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/short-bowel-syndrome-market

 

Short Bowel Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Short Bowel Syndrome Epidemiology Segmentation:

The Short Bowel Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Short Bowel Syndrome

  • Prevalent Cases of Short Bowel Syndrome by severity

  • Gender-specific Prevalence of Short Bowel Syndrome

  • Diagnosed Cases of Episodic and Chronic Short Bowel Syndrome

 

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ Short Bowel Syndrome Epidemiology Forecast

 

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Short Bowel Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Short Bowel Syndrome Therapies and Key Companies

  • Glepaglutide: Zealand Pharma

  • Apraglutide: Ironwood Pharmaceuticals

  • HM15912: Hanmi Pharmaceutical

  • Teduglutide: Shire

  • Pancreatic Enzyme: AbbVie

  • HM15912 Active: Hanmi Pharma

  • Somatropin: EMD Serono

  • ZP1848: Zealand Pharma

  • FE203799: VectivBio AG

  • Clinolipid: Baxter Healthcare

 

Discover more about therapies set to grab major Short Bowel Syndrome market share @ Short Bowel Syndrome Treatment Landscape

 

Short Bowel Syndrome Market Strengths

  • In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.

  • Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

 

Short Bowel Syndrome Market Opportunities

  • Several organizations are actively working to provide information and increase awareness of such disorders.

  • There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

 

Scope of the Short Bowel Syndrome Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others

  • Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others

  • Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies

  • Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Short Bowel Syndrome Unmet Needs, KOL’s views, Analyst’s views, Short Bowel Syndrome Market Access and Reimbursement

 

To know more about Short Bowel Syndrome companies working in the treatment market, visit @ Short Bowel Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Short Bowel Syndrome Market Report Introduction

2. Executive Summary for Short Bowel Syndrome

3. SWOT analysis of Short Bowel Syndrome

4. Short Bowel Syndrome Patient Share (%) Overview at a Glance

5. Short Bowel Syndrome Market Overview at a Glance

6. Short Bowel Syndrome Disease Background and Overview

7. Short Bowel Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Short Bowel Syndrome

9. Short Bowel Syndrome Current Treatment and Medical Practices

10. Short Bowel Syndrome Unmet Needs

11. Short Bowel Syndrome Emerging Therapies

12. Short Bowel Syndrome Market Outlook

13. Country-Wise Short Bowel Syndrome Market Analysis (2020–2034)

14. Short Bowel Syndrome Market Access and Reimbursement of Therapies

15. Short Bowel Syndrome Market Drivers

16. Short Bowel Syndrome Market Barriers

17. Short Bowel Syndrome Appendix

18. Short Bowel Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Short Bowel Syndrome Market Growth Projections 2024-2034: DelveInsight Analysis | Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma, Astion Pharma A/S, LEO Pharma

The Key Seborrhoeic Dermatitis Companies in the market include – Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others.

DelveInsight’s “Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Seborrhoeic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Seborrhoeic Dermatitis Market Forecast

 

Some of the key facts of the Seborrhoeic Dermatitis Market Report:

  • The Seborrhoeic Dermatitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In October 2024, Arcutis Biotherapeutics’ subsidiary, Arcutis Canada, has obtained Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3% for treating seborrheic dermatitis in patients aged nine and older. This marks the second international approval for ZORYVE, providing a new treatment option for over two million Canadians affected by this chronic skin condition. The approval was supported by positive findings from the pivotal Phase III STRATUM study, along with data from a Phase II long-term open-label extension trial and a Phase I pharmacokinetic study.

  • According to Sessevile et al. (n.d.), seborrheic dermatitis is more common in people with HIV infection, where it may present as a presenting symptom. According to estimates, the prevalence ranges from up to 85% among people with acquired immunodeficiency syndrome (AIDS) and around 35% among those with early HIV infection

  • According to Berl et al., dandruff, a non-inflammatory form of seborrheic dermatitis, is more common than 5% of seborrheic dermatitis worldwide

  • The current approach to treating seborrheic dermatitis is to loosen scale, lessen swelling and inflammation, and stop itching. The major objectives of the suggested treatments for seborrheic dermatitis are to eliminate the disease’s outward symptoms. A few preventative regimens have been identified because seborrheic dermatitis has been linked to sporadic relapses over several years

  • Key Seborrhoeic Dermatitis Companies: Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others

  • Key Seborrhoeic Dermatitis Therapies: ARQ 154, Omiganan, K40a, ASF1057, Azelaic Acid 15% Gel, ARQ-154, SEBORRHEAMEDIS Face Cream, PAC-14028, K301, Elidel, Ruxolitinib, and others

  • The Seborrhoeic Dermatitis epidemiology based on gender analyzed that males are most commonly affected in case of Seborrhoeic Dermatitis

  • The Seborrhoeic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Seborrhoeic Dermatitis pipeline products will significantly revolutionize the Seborrhoeic Dermatitis market dynamics.

 

Seborrhoeic Dermatitis Overview

Seborrheic dermatitis is a common, chronic skin condition characterized by red, inflamed skin with greasy or flaky white or yellow scales. It most commonly affects areas of the body where sebaceous (oil-producing) glands are most active, such as the scalp, face, ears, eyebrows, and chest.

 

Get a Free sample for the Seborrhoeic Dermatitis Market Report:

https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market

 

Seborrhoeic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Seborrhoeic Dermatitis Epidemiology Segmentation:

The Seborrhoeic Dermatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Seborrhoeic Dermatitis

  • Prevalent Cases of Seborrhoeic Dermatitis by severity

  • Gender-specific Prevalence of Seborrhoeic Dermatitis

  • Diagnosed Cases of Episodic and Chronic Seborrhoeic Dermatitis

 

Download the report to understand which factors are driving Seborrhoeic Dermatitis epidemiology trends @ Seborrhoeic Dermatitis Epidemiology Forecast

 

Seborrhoeic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Seborrhoeic Dermatitis market or expected to get launched during the study period. The analysis covers Seborrhoeic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Seborrhoeic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Seborrhoeic Dermatitis Therapies and Key Companies

  • ARQ 154: Arcutis Biotherapeutics

  • Omiganan: Cutanea Life Sciences

  • K40a: Moberg Pharma AB

  • ASF1057: Astion Pharma A/S

  • Azelaic Acid 15% Gel: LEO Pharma

  • ARQ-154: Arcutis Biotherapeutics

  • Omiganan: Maruho Co., Ltd.

  • SEBORRHEAMEDIS Face Cream: Kamedis Ltd.

  • PAC-14028: Amorepacific Corporation

  • K301: Moberg Pharma AB

  • Elidel: Novartis

  • Ruxolitinib: Incyte Corporation

 

Discover more about therapies set to grab major Seborrhoeic Dermatitis market share @ Seborrhoeic Dermatitis Treatment Market

 

Seborrhoeic Dermatitis Market Strengths

  • The use of off-label branded and generic prescription medications targeted at individual symptoms of Seborrhoeic Dermatitis, including antiepileptics, antipsychotics, antidepressants and benzodiazepines

  • Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Seborrhoeic Dermatitis

 

Seborrhoeic Dermatitis Market Opportunities

  • Challenges in diagnoses

  • Development of novel therapies

  • Limitations in gene therapy

  • Poor disease understanding

  • Clinical biomarkers

 

Scope of the Seborrhoeic Dermatitis Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Seborrhoeic Dermatitis Companies: Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others

  • Key Seborrhoeic Dermatitis Therapies: ARQ 154, Omiganan, K40a, ASF1057, Azelaic Acid 15% Gel, ARQ-154, SEBORRHEAMEDIS Face Cream, PAC-14028, K301, Elidel, Ruxolitinib, and others

  • Seborrhoeic Dermatitis Therapeutic Assessment: Seborrhoeic Dermatitis current marketed and Seborrhoeic Dermatitis emerging therapies

  • Seborrhoeic Dermatitis Market Dynamics: Seborrhoeic Dermatitis market drivers and Seborrhoeic Dermatitis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Seborrhoeic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Seborrhoeic Dermatitis Market Access and Reimbursement

 

To know more about Seborrhoeic Dermatitis companies working in the treatment market, visit @ Seborrhoeic Dermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Seborrhoeic Dermatitis Market Report Introduction

2. Executive Summary for Seborrhoeic Dermatitis

3. SWOT analysis of Seborrhoeic Dermatitis

4. Seborrhoeic Dermatitis Patient Share (%) Overview at a Glance

5. Seborrhoeic Dermatitis Market Overview at a Glance

6. Seborrhoeic Dermatitis Disease Background and Overview

7. Seborrhoeic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Seborrhoeic Dermatitis

9. Seborrhoeic Dermatitis Current Treatment and Medical Practices

10. Seborrhoeic Dermatitis Unmet Needs

11. Seborrhoeic Dermatitis Emerging Therapies

12. Seborrhoeic Dermatitis Market Outlook

13. Country-Wise Seborrhoeic Dermatitis Market Analysis (2019–2032)

14. Seborrhoeic Dermatitis Market Access and Reimbursement of Therapies

15. Seborrhoeic Dermatitis Market Drivers

16. Seborrhoeic Dermatitis Market Barriers

17. Seborrhoeic Dermatitis Appendix

18. Seborrhoeic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: LasVegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma, Astion Pharma A/S, LEO Pharma

Research Publication Reveals Key Insight to Improve Care for Stroke Patients Across the World

St. Louis, MO – A new study titled “Predictors of In-Hospital Mortality Among Patients With Acute Stroke: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database” led by Azhar Ushmani, Sandipkumar Patel, Priji Prasad Jalaja, Dheeraj Kommineni, Chrishanti Anna Joseph, and Naga Venkata Satish Babu Bodapati has uncovered crucial factors contributing to in-hospital mortality in stroke patients. The research promises to not only improve patient outcomes but also save billions of dollars in healthcare costs.

The study identifies advanced age, cardiovascular and metabolic comorbidities, and hospital resource utilization as the leading factors affecting stroke-related deaths in hospitals. This emphasizes the urgent need for early risk stratification and the development of personalized care strategies for high-risk patients.

Ms. Isabelle Gautier, Associate Journalist at Alpine Vision Media, stated, “This study offers crucial insights into the factors that determine in-hospital mortality among stroke patients. By recognizing these predictors early, healthcare professionals can implement more targeted interventions, ultimately improving survival rates and reducing the strain on healthcare systems.In the United States alone, stroke remains a leading cause of death, with over 795,000 new cases each year. The study’s findings, which highlight the importance of early risk identification, could significantly reduce the country’s stroke mortality rates. Furthermore, by improving patient care, the research is expected to save billions of dollars in healthcare costs annually, with potential savings exceeding $10 billion for the U.S. healthcare system.”

Experts in stroke care worldwide are already recognizing the impact of this research. Dr. Alejandro Rodríguez, a leading neurologist from Argentina, and Dr. Mahmoud Al-Sayed, a renowned stroke specialist from Egypt, have both been at the forefront of advancing stroke care in their respective countries. Their ongoing efforts to improve early diagnosis and intervention for stroke patients in underserved regions are making a significant difference in global healthcare outcomes.

The findings of this study are not just relevant to high-income countries but have the potential to revolutionize stroke care worldwide. In regions with limited healthcare resources, where the burden of stroke mortality remains high, early identification and targeted interventions could save countless lives. “With over 13.7 million new cases of stroke occurring each year globally, this research holds the potential to transform the way stroke care is delivered,” stated Ms. Gautier. By improving survival rates and optimizing resource allocation, the study paves the way for substantial cost savings and better patient outcomes on a global scale.

Citation: Ushmani A, Patel S, Prasad Jalaja, et al. (March 29, 2025) Predictors of In-Hospital Mortality Among Patients With Acute Stroke: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database. Cureus 17(3): e81403. DOI 10.7759/cureus.81403

Media Contact
Company Name: Alpine Vision Media
Contact Person: Isabelle Gautier
Email: Send Email
Country: Switzerland
Website: https://alpinevisionmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Research Publication Reveals Key Insight to Improve Care for Stroke Patients Across the World

Ascites Market to Expand Significantly by 2034, States DelveInsight Report | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, Roche

The Key Ascites Companies in the market include – PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others.

 

DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Ascites market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ascites Market Forecast

 

Some of the key facts of the Ascites Market Report:

  • The Ascites market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In November 2024, Pharmanovia, an international pharmaceutical company specializing in commercializing innovative therapies and enhancing the lifecycle of established medicines, announced the expansion of its oncology portfolio through a new licensing agreement for catumaxomab, aimed at treating malignant ascites.

  • In 2023, the US ascites market size attributed to cirrhosis was valued at over USD 800 million, with projections indicating growth throughout the forecast period (2024–2034).

  • In 2023, the market size for diuretics used in the treatment of ascites caused by cirrhosis in the US was estimated to be approximately USD 140 million.

  • In 2023, the US had the highest number of ascites cases caused by cirrhosis among the 7MM, exceeding 152,000 cases. This figure is expected to rise throughout the forecast period (2024-2034).

  • In 2023, breast cancer contributed the highest number of ascites cases caused by malignancies in the US, with approximately 13,000 cases, followed by colorectal cancer.

  • In the US, severity-specific cases of Grade II and III ascites totaled approximately 125,000 in 2023.

  • Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others

  • Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others

  • The Ascites market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics.

 

Ascites Overview

A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. Ascites may be painful in extreme cases.

 

Get a Free sample for the Ascites Market Report

https://www.delveinsight.com/sample-request/ascites-market

 

Ascites Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ascites Epidemiology Segmentation:

The Ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Ascites

  • Prevalent Cases of Ascites by severity

  • Gender-specific Prevalence of Ascites

  • Diagnosed Cases of Episodic and Chronic Ascites

 

Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast

 

Ascites Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ascites Therapies and Key Companies

  • PHIN-214: PharmaIN

  • BIV201 (Terlipressin): BioVie

  • OCE-205: Ocelot Bio

 

Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market

 

Ascites Market Strengths

  • The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase in the patient population of ascites

 

Ascites Market Opportunities

  • Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies

 

Scope of the Ascites Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others

  • Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others

  • Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies

  • Ascites Market Dynamics: Ascites market drivers and Ascites market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement

 

To know more about Ascites companies working in the treatment market, visit @ Ascites Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Ascites Market Report Introduction

2. Executive Summary for Ascites

3. SWOT analysis of Ascites

4. Ascites Patient Share (%) Overview at a Glance

5. Ascites Market Overview at a Glance

6. Ascites Disease Background and Overview

7. Ascites Epidemiology and Patient Population

8. Country-Specific Patient Population of Ascites

9. Ascites Current Treatment and Medical Practices

10. Ascites Unmet Needs

11. Ascites Emerging Therapies

12. Ascites Market Outlook

13. Country-Wise Ascites Market Analysis (2020–2034)

14. Ascites Market Access and Reimbursement of Therapies

15. Ascites Market Drivers

16. Ascites Market Barriers

17. Ascites Appendix

18. Ascites Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ascites Market to Expand Significantly by 2034, States DelveInsight Report | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, Roche